Freedom to Move…All Over the World
Clinically studied Serratrin offers a lower dose and faster efficacy than most of the top-selling joint comfort and mobility products on the market.
Serratrin is a novel, full-spectrum Boswellia serrata extract, standardized to ≥ 30% boswellic acids. It is derived from two different extracts of Boswellia and formulated for maximum benefits. Boswellia has been used in the Ayurvedic medicine tradition for thousands of years. Serratrin takes this tradition and scientifically improves it for modern day use.
Serratrin was developed by Laila Nutraceuticals, a division of Laila Group, India’s leading producer of herbal extracts. The Research Center is accredited by the Government of India, Department of Scientific and Industrial Research (DSIR) and has partnered with various universities in its PhD research projects. The Laila Impex Research Center also has partnerships with Georgetown University in Washington, D.C., Ohio State University Medical Center, University of Kansas Medical Center, University of California, Davis, and Vienna Medical College in Austria.
A powerful, targeted anti-inflammatory Serratrin works by supporting a healthy inflammation metabolism. It has been shown in preclinical research to down-regulate key mediators of inflammatory pain, including 5-Lipoxygenase, Leukotriene B4, Prostaglandin E2, and TNF-α.
Serratrin was also shown to:
The pentacyclic triterpenic acids, named boswellic acids (BAs), present in the gum resin of Boswellia serrata, are the main constituents responsible for its anti-inflammatory property. Suppression of LT synthesis by inhibiting 5-LOX is considered the primary mechanism underlying their anti-inflammatory effect. BAs are specific and non-redox inhibitors of 5-LOX, and they do not affect 12-LOX and COX activities